ISRCTN34043997CompletedPhase 2
Randomised phase II trial of cediranib (AZD2171) versus placebo in addition to cisplatin/gemcitabine chemotherapy for patients with advanced biliary tract cancers
niversity College London (UCL) (UK)0 sites124 target enrollmentStarted: June 30, 2010Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 124
Study Overview
Brief Summary
2015 Results article in https://www.ncbi.nlm.nih.gov/pubmed/26179201 results
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Current inclusion criteria as of 03/05/2011:
- •There will be no exception to the eligibility requirements at the time of randomisation. Queries in relation to the eligibility criteria should be addressed prior to calling for randomisation.
- •1. A histopathological/cytological diagnosis of non-resectable or recurrent/metastatic biliary tract carcinoma (intra- or extra-hepatic), gall bladder or ampullary carcinoma
- •2. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
- •3. Aged greater than or equal to 18 years, either sex
- •4. Estimated life expectancy greater than 3 months
- •5. Adequate haematological function:
- •5.1. Haemoglobin greater than 10 g/dl (prior transfusions for patients with low haemoglobin are allowed)
- •5.2. White blood cell count (WBC) greater than 3.0 x 10^9/L
- •5.3. Absolute neutrophil count (ANC) greater than 1.5 x 10^9/L
- •5.4. Platelet count greater than 100 x 10^9/L (updated on 03/05/2011)
- •6. Adequate liver function:
- •6.1. Total bilirubin less than or equal to 1.5 x upper limit of normal (ULN) (except for patients with known documented cases of Gilbert's syndrome)
- •6.2. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) less than or equal to 2.5 x ULN (if liver metastases are present, ALT or AST less than 5 x ULN) (updated on 03/05/2011)
- •6.3. Alkaline phosphatase less than or equal to 5 x ULN
- •7. Adequate renal function:
- •7.1. Serum urea less than 1.5 x ULN
- •7.2. Serum creatinine less than 1.5 x ULN
- •7.3. Calculated glomerular filtration rate (GFR) greater than or equal to 45 mL/min. If the calculated GFR is below 45mL/min, isotope ethylenediaminetetraacetic acid (EDTA) confirmation of adequate renal function is required.
- •8. No evidence of active uncontrolled infection (patients on long-term antibiotics are eligible provided signs of active infection have resolved)
- •9. Women of child-bearing potential must have a negative pregnancy test prior to study entry and be using an adequate contraception method, which must be continued for 3 months after completion of chemotherapy
- •10. Patient must have given written informed consent
- •The following prior therapy is allowed (provided there has been a full recovery):
- •11. Surgery - patients may have undergone a non-curative operation (i.e. R2 resection [with macroscopic residual disease] or palliative bypass surgery only). Patients who have previously undergone curative surgery, must have evidence of non-resectable disease relapse requiring systemic chemotherapy prior to study entry.
- •12. Radiotherapy - patients may have received prior radiotherapy (with or without radio-sensitising low-dose chemotherapy) for localised disease. However, there must be clear evidence of disease progression prior to inclusion in this study.
- •13. Prior systemic chemotherapy for locally advanced or metastatic disease is not allowed, unless it has been given in low-dose as a radio-sensitiser in conjunction with radiotherapy. Prior adjuvant chemotherapy is allowed provided neither gemcitabine nor cisplatin were used and the treatment was completed at least 6 months before trial e
Exclusion Criteria
- •1. Significant haemorrhage (greater than 30 mL bleeding/episode in previous 3 months) or haemoptysis (greater than 5 mL fresh blood) within 4 weeks of randomisation.
- •2. Patients with history of poorly controlled hypertension with resting blood pressure greater than 150/100 mmHg in the presence or absence of a stable regimen of anti-hypertensive therapy, or patients who are requiring maximal doses of calcium channel blockers to stabilise blood pressure
- •3. Incomplete recovery (Common Toxicity Criteria of Adverse Events [CTCAE] grade greater than 1) from previous anti-cancer therapy (except haematological toxicity - see inclusion criteria for adequate haematological function), or alopecia
- •4. Unresolved biliary tree obstruction
- •5. Any evidence of severe or uncontrolled systemic diseases which, in the view of the investigator, makes it undesirable for the patient to participate in the trial (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease)
- •6. Untreated unstable brain or meningeal metastases. Patients with radiological evidence of stable brain metastases are eligible providing that they are asymptomatic and either do not require corticosteroids or have been treated with corticosteroids, with clinical and radiological evidence of stabilisation at least 10 days after discontinuation of steroids.
- •7. Greater than +1 proteinuria on two consecutive dipsticks taken no less than 1 week apart unless urinary protein less than 1.5 g in a 24-hour period or protein/creatinine ratio less than 1.5
- •8. History of significant gastrointestinal impairment, as judged by the Principal Investigator that would significantly affect the absorption of cediranib
- •9. Mean QTc with Bazetts correction greater than 480 msec in screening electrocardiogram (ECG) or history of familial long QT syndrome
- •10. Recent (less than 14 days) major thoracic or abdominal surgery prior to randomisation, or a surgical incision that is not fully healed
- •11. Pregnant or breast-feeding women
- •12. Known hypersensitivity to cediranib or any of its excipients
- •13. Known risk of the patient transmitting human immunodeficiency virus (HIV), hepatitis B or C via infected blood
- •14. Treatment with an investigational drug within 30 days prior to randomisation
- •15. Other concomitant anti-cancer therapy (except steroids)
- •16. Patients undergoing current treatment with curative intent
- •17. History of prior malignancy that will interfere with the response evaluation (exceptions include in-situ carcinoma of the cervix treated by cone-biopsy/resection, non-metastatic basal and/or squamous cell carcinomas of the skin, any early stage (stage I) malignancy adequately resected for cure greater than 5 years previously)
- •18. Any psychiatric or other disorder (e.g. symptomatic brain metastases) likely to impact on informed consent
- •N.B. Whilst not excluded, patients with significant impaired hearing must be made aware of potential ototoxicity and may choose not to be included. If included, it is recommended that audiograms be carried out at baseline and prior to cycle 2.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Clinical trial testing the drug cediranib(AZD2171)against placebo with cisplatin / gemcitabine chemotherapy for patients with advanced biliary tract cancersbiliary tract carcinomas (including gallbladder cancer and cholangiocarcinomas)MedDRA version: 17.0 Level: LLT Classification code 10004595 Term: Bile duct cancer NOS System Organ Class: 100000004864MedDRA version: 17.0 Level: LLT Classification code 10008594 Term: Cholangiocarcinoma non-resectable System Organ Class: 100000004864MedDRA version: 17.0 Level: LLT Classification code 10017617 Term: Gallbladder cancer non-resectable System Organ Class: 100000004864EUCTR2009-013408-30-GBniversity College London124
Completed
Phase 2
COSAK trial: cediranib and saracatanib/placebo in relapsed clear cell renal cancerClear cell renal cancerMalignant neoplasm of kidney, except renal pelvisCancerISRCTN56886343Common Services Agency (UK)138
Completed
Phase 2
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With DocetaxelHormone Refractory Prostate CancerRecurrent Prostate CancerNCT01260688National Cancer Institute (NCI)22
Completed
Phase 2
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial CancerEndometrial AdenocarcinomaEndometrial Adenosquamous CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Serous AdenocarcinomaRecurrent Uterine Corpus CarcinomaNCT01132820National Cancer Institute (NCI)53
Active, not recruiting
Phase 1
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural MesotheliomaEpithelioid MesotheliomaPleural Malignant MesotheliomaRecurrent Malignant MesotheliomaSarcomatoid MesotheliomaNCT01064648National Cancer Institute (NCI)117